Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Despite broader market challenges like the Dow's 1.7% decline and inflation concerns, Gilead's stock rose 18% over the last quarter, potentially buoyed by its robust Q4 earnings report and ...

The company advised voting against these proposals, slated for discussion at the upcoming annual meeting. Despite broader market challenges like the Dow's 1.7% decline and inflation concerns, Gilead's ...

Eventide Gilead Fund Inst (ETILX) stock price is 48.91 and Eventide Gilead Fund Inst (ETILX) 10-day simple moving average is 49.52. Eventide Gilead Fund Inst (ETILX) stock price is 48.91 and ...

Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $80.00 to $120.00 in a research note on ...